Activating point mutations in platelet-derived growth factor receptor alpha (PDGFRA) were present in 6/17 (35.3%) of PMMRDIA, much more often than in supratentorial, high-grade IDH-mutant astrocytomas (9.1%). The gene discussed is PDGFRA; the disease is astrocytoma (excluding glioblastoma).